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Introduction
P ROSTATE CANCER is the most common malignancy in men in the western world. 1 In 2005, 9,500 men in the Netherlands received a diagnosis of prostate cancer, and this number is expected to increase to 15,000 by the year 2015. 2 Brachytherapy is one of the treatment options for localized prostate cancer. Sometimes brachytherapy patients undergo volume-reducing hormone therapy because of a large prostate volume or high-risk tumor characteristics (eg, high prostate-specific antigen [PSA] levels, high Gleason scores, or a high tumor stage).
Prostate cancer can affect general health-related quality of life (HRQOL) (e.g., physical, psychological, and social func-tioning) and disease-specific HRQOL (eg, urinary, sexual, and bowel functioning). [3] [4] [5] [6] Differences in effects on HRQOL between treatment methods exist. In this study, we compared "brachytherapy" with "brachytherapy with volumereducing hormone therapy" on HRQOL aspects.
Urinary complaints after prostate brachytherapy are common but only rarely severe. 7 Moreover, they appear to peak 1 month after brachytherapy and subsequently return to their baseline values after 1 year. 8 Compared with a control group of patients with prostate cancer who were not treated, brachytherapy patients did not differ in overall urinary HRQOL at follow-up (mean ϭ 26 months). 9 Another study, however, found that during a 4-year period (2.6 years to 6.2 years after treatment), urinary incontinence worsened in patients treated with brachytherapy. 6 Patients receiving hormone therapy only reported more physical discomfort 1 year after diagnosis compared with men who did not receive hormone therapy. 10 Furthermore, among men who were sexually potent before diagnosis, 80% of patients treated with hormone therapy reported being impotent after one year. 10 In addition, patients who had received hormone therapy reported reduced energy, and poorer sexual and urinary function; they were more bothered by their urinary and sexual function than patients undergoing radical prostatectomy or radiotherapy. 5 Patients treated with hormone therapy for at least 12 months had osteoporosis, unfavorable body composition, sexual dysfunction, and reduced overall HRQOL scores. 11 To summarize, both brachytherapy and hormone therapy appear to have a negative influence on HRQOL. To the best of our knowledge, however, only one study has been published that compared HRQOL between prostate cancer patients treated with brachytherapy versus brachytherapy with volume-reducing hormone therapy. 12 Compared with patients treated with brachytherapy, brachytherapy with volume-reducing hormone therapy led to lower HRQOL in all domains 29 months after treatment. This was significant and clinically relevant for urinary bother, sexual function/ bother, and hormone function/bother. Despite its relevance, that study was cross-sectional and could therefore not register changes between treatments over time. Therefore, we examined the short-term influence of brachytherapy and brachytherapy with volume-reducing hormone therapy on HRQOL in patients with T 1 -T 2 prostate cancer in a prospective study.
Patients and Methods

Setting and participants
This study was conducted at the Catharina Hospital, Eindhoven, the Netherlands. A total of 386 patients who had received a diagnosis of T 1 -T 2 prostate cancer in the period between July 2000 and November 2004 were asked to participate in this study.
All patients were treated with I-125 prostate brachytherapy. Brachytherapy was often applied with volume-reducing hormone therapy to reduce the volume of the prostate in patients with prostate gland volume Ͼ60 cc or to exterminate the influence of testosterone on the tumor in highrisk patients. 13 A majority was treated with a combination of antiandrogen and LHRH (luteinizing hormone-releasing hormone) analogues (70%), some were treated with only an-tiandrogens (19%), and some were treated with only LHRH analogues (11%) ( Table 1) . Duration of androgen ablation was 9 months, starting 3 months before I-125 implantation.
Data collection
Patients were asked to complete our measure at three points in time: Before treatment (T1), 6 weeks after the start of treatment (T2), and 3 months after treatment (T3). Thus, in the case of patients treated with brachytherapy only, they received the first questionnaire before brachytherapy. In the case of patients treated with brachytherapy with volume-reducing hormone therapy, they received the first questionnaire before the start of hormone therapy and thus 3 months before brachytherapy. Measurements two and three were similar in both groups-namely 6 weeks and 3 months after brachytherapy.
Patients were reassured that nonparticipation did not have any consequences for their follow-up care or treatment. Returned questionnaires only contained a study number that guaranteed anonymity. The Medical Ethics Committee of Catharina Hospital approved this study. Written informed consent was obtained from every patient after the study procedure had been fully explained.
Measures
Patient data, including age, tumor-node-metastasis-classification, 14 pretreatment PSA, Gleason score, grade, and primary treatment were derived from patients' medical records.
The European Organization of Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30) version 3.0 was used to measure global HRQOL. 15 This questionnaire contains five functional scales (physical, role, emotional, cognitive, and social functioning), a global HRQOL scale, three symptom scales (nausea and vomiting, fatigue, and pain), and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).
Urologic, bowel, and sexual functioning were measured with the EORTC-QLQ PR25. 16 This questionnaire contains five scales (urinary problems, bowel symptoms and functioning, treatment-related functions, sexual functioning, and sexual activity).
The response format of the EORTC-QLQ-C30 and the EORTC-QLQ-PR25 was a Likert scale. According to standard scoring procedures, all scales were linearly converted to a 0 to 100 scale, with higher scores indicating better functioning.
Statistical analyses
The Statistical Package for the Social Sciences (SPSS 12.0.0 for Windows) was used for all data analyses. Patient characteristics and clinical parameters were described in percentages and were analyzed using chi-square tests for categorical variables.
Linear regression analyses were carried out to investigate the association between patient characteristics (age, stage, grade, pretreatment PSA and Gleason score) with the subscale scores of the EORTC-QLQ-C30 and EORTC-QLQ-PR25. On the basis of the univariate results, multivariate models were constructed to determine which of the patient and tumor characteristics were associated independently with HRQOL outcomes. We controlled for these variables in the analysis of variance (general linear repeated-measures model), which was used to compare HRQOL scores between patients treated with brachytherapy or brachytherapy with volume-reducing hormone therapy, at three points in time.
P values are presented for within-subjects effects over time (before treatment and 6 weeks and 3 months after treatment), between-subjects effects for treatment (brachytherapy or brachytherapy with volume-reducing hormone therapy), and time by treatment interaction effects. These P values are all Greenhouse-Geisser corrected except for the subscale constipation, where sphericity was assumed. P values less than 0.01 were considered statistically significant and are included in the text. P values less then 0.05 are only mentioned in the tables. We used Norman's "rule of thumb" that the threshold of discrimination for clinically relevant changes in HRQOL for a chronic disease appears to be approximately half a standard deviation. 17
Results
Sociodemographic characteristics
Three hundred and twelve (81%) of the 386 suitable prostate brachytherapy patients returned a completed questionnaire at least once (Table 1 ). Before treatment, 295 patients (17 missing) returned the set of questionnaires; 6 weeks after treatment, 266 patients (46 missing) returned questionnaires; and 3 months after treatment, 263 patients (49 missing) returned questionnaires. All of them underwent I-125 brachytherapy, and 79 of them also underwent volume-reducing hormone therapy. No statistically significant differences in age at the time of the survey, Gleason score, pretreatment PSA, stage, and grade were found between both treatment groups. a Grade was based on the tumor-node-metastasis clinical classification. 14 Grade 1 is comparable to a Gleason score of 2 to 4, grade 2 is comparable to a Gleason score of 5 to 7, and grade 3 is comparable to a Gleason score of 8 to 10.
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PSA ϭ prostate-specific antigen; LHRH ϭ luteinizing hormone-releasing hormone.
Differences in HRQOL over time
EORTC-QLQ-C30 subscale scores in both patient groups changed significantly between the three measurements. Globally, scores decreased after treatment, increased again between 6 weeks and 3 months after treatment, but never reached the pretreatment level again. Statistically significant and clinically relevant differences 17 between measurements 1, 2, and 3 were found for global health status (P Ͻ 0.001), role functioning (P Ͻ 0.001), social functioning (P Ͻ 0.001), fatigue (P Ͻ 0.001), pain (P Ͻ 0.001), and insomnia (P Ͻ 0.001). For example, values for the subscale global health status decreased significantly 6 weeks after treatment, but after 3 months, the self-reported global health status improved again for both treatment groups.
Scores on the EORTC-QLQ-PR25 showed a similar pattern; they decreased after treatment, followed by an increase between 6 weeks and 3 months after treatment, but they also failed to reach pretreatment levels. Repeated measures showed significant and clinically relevant decreases over time for the subscales bowel symptoms and functioning (P Ͻ 0.001), and treatment-related functions (P Ͻ 0.001). These findings demonstrate an increase of these prostate cancer-related complaints, regardless of the treatment. Incontinence aids were used by too few respondents, so they were discarded from analysis.
Differences in HRQOL between treatment methods
Statistically significant effects for treatment (brachytherapy versus brachytherapy with volume-reducing hormone therapy) were not found for the subscales of the EORTC-QLQ-C30.
For the EORTC-QLQ-PR25, statistically significant and clinically relevant differences between the two treatment methods were found for the subscales treatment-related functions (P Ͻ 0.001) and sexual functioning (P Ͻ 0.001). The average scores for the significant subscales were lower for patients who received brachytherapy with volume-reducing hormone therapy compared with patients who were treated with brachytherapy only.
Differences in HRQOL over time for treatment methods
Significant time by treatment interaction effects for the subscales of both questionnaires was only found for treatment-related functions (P Ͻ 0.001). It appeared that a greater reduction in HRQOL was found over time on this subscale when receiving brachytherapy with volume-reducing hormone therapy in contrast to treatment with brachytherapy only.
Discussion
This study examined the short-term influence of brachytherapy and brachytherapy with volume-reducing hormone therapy on HRQOL in patients with T 1 -T 2 prostate cancer in a prospective study. Both brachytherapy and brachytherapy with volume-reducing hormone therapy negatively influenced HRQOL (global health status, role functioning, social functioning, pain, insomnia) and caused treatment-related problems (bowel symptoms and functioning, treatment-related functions, and sexual functioning) 6 weeks and 3 months after treatment. The differences in HRQOL be-tween brachytherapy and brachytherapy with volume-reducing hormone therapy were small.
To date, no prospective studies have been published that have as a primary objective to compare HRQOL over time between patients treated with either brachytherapy or brachytherapy with volume-reducing hormone therapy. Therefore, our results are difficult to compare with previous findings. A recent prospective study among T 1 and T 2 prostate cancer patients, however, concluded that those treated with brachytherapy reported having long-lasting urinary irritation, bowel and sexual symptoms, and transient problems with vitality or hormone function. Furthermore, adjuvant hormone therapy was associated with worse outcomes across multiple quality-of-life domains among patients who were receiving brachytherapy. 18 Despite the fact that comparing brachytherapy patients treated with and without volume-reducing hormone therapy was not the objective of that study and despite the fact that different questionnaires were used, it partly confirms our results.
A Dutch study among 127 patients with low-stage prostate cancer who were treated with brachytherapy that did use the same questionnaires also found a decrease in HRQOL 4 weeks after treatment. 19 One year after implant, HRQOL of the patients was at least equal to preimplant scores, which suggests that many of the negative effects may recover in the long term. This confirms the reports that demonstrate that acute side effects after brachytherapy for prostate cancer appear to peak 1 month after brachytherapy and subsequently return to their baseline values at 1 year. 8 In addition, after brachytherapy, dysuria is a relatively common complaint, but at approximately 45 months after therapy, it appears to have been resolved in almost all patients. 7 According to a Japanese study, morbidity (associated with brachytherapy followed by external beam radiotherapy) was highest during the first month of treatment, and it affected HRQOL significantly. Most outcome measures, however, showed a recovery to baseline levels 12 months after radiation therapy. 20 Finally, a Swedish study on HRQOL after external beam radiotherapy and brachytherapy revealed that the negative contribution from neoadjuvant androgen deprivation therapy on symptom development seemed to be substantial but mostly transitory. 21 Our study also showed a decrease in HRQOL after treatment followed by an increase between 6 weeks and 3 months after treatment. Unlike the studies described above, however, our HRQOL scores failed to reach the pretreatment level again within 3 months. This period is probably too short to show a complete recovery. An additional follow-up measurement to this study (Ͼ1 year after treatment) could possibly demonstrate a complete recovery in HRQOL.
Patient-reported analyses of the effects of volume-reducing hormone therapy on HRQOL after brachytherapy are scarce. Only one German study compared HRQOL in prostate cancer patients (n ϭ 134) who were treated with only brachytherapy with patients who received brachytherapy with volume-reducing hormone therapy. 12 That study reported lower HRQOL on all domains of the Expanded Prostate Cancer Index questionnaire in patients who were treated with brachytherapy with volume-reducing hormone therapy compared with patients who were treated with brachytherapy only. Two major drawbacks of that study, (24) 58 (21) 49 (21) Ͻ0.050 Ͻ0.050
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Incontinence aids were used by too few respondents (7 total) to be statistically significant.
All scales were linearly converted to a 0 to 100 scale, with higher scores indicating better functioning. P values are given for the effects of time, treatment, and time * treatment. P values less than 0.01 were considered statistically significant and are included in the text. P values less then 0. however, were its cross-sectional nature and the fact that it compared HRQOL 2 to 50 months after treatment.
In our study, we did not find a HRQOL difference in all domains between the two treatments. It appeared that prostate cancer patients who received brachytherapy with volume-reducing hormone therapy experienced more negative effects of their treatment (lower treatment-related functions and worse sexual functioning) compared with patients who were treated with brachytherapy only. Comparison of the findings of both studies is not possible, given the different questionnaire and the substantial difference in the timing of the measures.
Other studies 22-24 that compared both treatment groups did not include HRQOL measures. Potency rates decreased significantly after brachytherapy with volume-reducing hormone therapy compared with brachytherapy alone 5 years after treatment (76% versus 52%). 22 Furthermore, rectal function after brachytherapy with volume-reducing hormone therapy was slightly worse than after brachytherapy only. This difference, however, did not reach statistical significance. 23 Finally, volume-reducing hormone therapy was found to be associated with an significantly increased risk of urinary retention. 24 Sexual functioning was both statistically worse in patients in the volume-reducing hormone therapy group before treatment compared with the brachytherapy only group. The difference in sexual functioning, however, between patients treated with or without volume-reducing hormone therapy was probably not related to therapy, because a statistically significant difference was already present before the onset of therapy. The fact that sexual functioning was not significant in the "time by treatment analysis" confirms this idea. The subscale treatment-related functions was the only scale that showed a difference over time, between treatments, and time by treatment.
The present study has some limitations. First, maybe not all hormone treatments are comparable. In this study, the majority of patients were treated with antiandrogen or LHRH analogues, or a combination of both (89%). There were patients (11%) who received other hormone therapies, such as cyproterone acetate or leuprorelin acetate. These therapies may have a different effect on HRQOL. This could not be evaluated in this study because of the low number of patients receiving these treatments.
In addition, comorbidity is a factor that can influence HRQOL and is therefore often controlled for in HRQOL studies. [25] [26] [27] Comorbidity might also interfere with our results and is not corrected for in this research, because information on comorbidity was not available. We have no reason to suspect, however, that comorbidity is present more in either treatment group.
Finally and most importantly, the current study only focused on relatively short-term effects (up to 3 months). It is possible that, after treatment, patients who were treated with hormone therapy report a lower HRQOL because they are still bothered by the effects of hormone therapy, which wear off more slowly compared with the treatment effects of brachytherapy. A long-term prospective study on long-term effects on HRQOL is needed to obtain a more comprehensive view of the consequences of a specific treatment modality over time.
Conclusion
We think that the results of this study add importantly to the limited information available on HRQOL in patients with prostate cancer who receive brachytherapy or brachytherapy with volume-reducing hormone therapy, especially because of its prospective nature. Insight into the effects of brachytherapy on HRQOL is important as this therapy becomes more standard in the treatment of men with earlystage prostate cancer.
The differences in HRQOL in patients who are treated with brachytherapy or brachytherapy with volume-reducing hormone therapy are small. Both treatments cause a decrease in HRQOL and increase in treatment-related problems. Our results can help to identify the problems patients face after brachytherapy with or without hormone therapy; these problems deserve additional attention during the period of recovery. Long-term prospective studies on the long-term effects on HRQOL are needed, however, to obtain a more comprehensive view of the consequences of a specific treatment modality over time.
